# Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

> **NCT02365532** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 60 (actual)

## Conditions studied

- Long QT Syndrome

## Interventions

- **DRUG:** GS-6615
- **DRUG:** Placebo to match GS-6615
- **DRUG:** Placebo to match dofetilide
- **DRUG:** Dofetilide

## Key facts

- **NCT ID:** NCT02365532
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2015-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02365532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02365532, "Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02365532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*